{"DataElement":{"publicId":"7351599","version":"1","preferredName":"CDISC Domain Patient Clinical Trial Eligibility Determination Children's Oncology Group Protocol Identifier","preferredDefinition":"Indication as to the Childrens Oncology Group protocol, or protocols, for which the patient is eligible to enroll.","longName":"IE_IEELIG _PROT","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"7351594","version":"1","preferredName":"CDISC Domain Patient Clinical Trial Eligibility Determination","preferredDefinition":"A collection of data variables or metadata for use with a Clinical Data Interchange Standards Consortium (CDISC) data submission. Representative examples include Laboratory (LB), Subject Characteristics (SC), and Trial Summary (TS)._A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes._The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","longName":"6409461v1.0:7351592v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"6409461","version":"1","preferredName":"CDISC Domain","preferredDefinition":"A collection of data variables or metadata for use with a Clinical Data Interchange Standards Consortium (CDISC) data submission. Representative examples include Laboratory (LB), Subject Characteristics (SC), and Trial Summary (TS).","longName":"C103182","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CDISC Domain","conceptCode":"C103182","definition":"A collection of data variables or metadata for use with a Clinical Data Interchange Standards Consortium (CDISC) data submission. Representative examples include Laboratory (LB), Subject Characteristics (SC), and Trial Summary (TS).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"740DB30A-FDF9-32A4-E053-F662850A51CF","latestVersionIndicator":"Yes","beginDate":"2018-08-22","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-08-22","modifiedBy":"ONEDATA","dateModified":"2018-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7351592","version":"1","preferredName":"Patient Clinical Trial Eligibility Determination","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.:A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.:The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","longName":"C16960:C71104:C25171","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Clinical Trial","conceptCode":"C71104","definition":"A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Eligibility Determination","conceptCode":"C25171","definition":"The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA599539-91B0-62EB-E053-4EBD850ACD9A","latestVersionIndicator":"Yes","beginDate":"2020-07-13","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-07-13","modifiedBy":"ONEDATA","dateModified":"2020-07-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA599539-91C1-62EB-E053-4EBD850ACD9A","latestVersionIndicator":"Yes","beginDate":"2020-07-13","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-07-13","modifiedBy":"SPRINGERL","dateModified":"2020-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7349519","version":"1","preferredName":"Children's Oncology Group Protocol Identifier","preferredDefinition":"An NCI-supported clinical cooperative group formed by the merger of the four national pediatric cancer research organizations: the Children's Cancer Group, the Intergroup Rhabdomyosarcoma Study Group, the National Wilms Tumor Study Group, and the Pediatric Oncology Group. The primary objective of the organization is to conduct clinical trials of new therapies for childhood and adolescent cancer. COG develops and coordinates clinical trials conducted at the 238 member institutions that include cancer centers of all major universities and teaching hospitals throughout the U.S. and Canada, as well as sites in Europe and Australia. COG members include over 5000 cancer researchers._A rule which guides how an activity should be performed._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.","longName":"7349519v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"3126125","version":"1","preferredName":"Other","longName":"3126125","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8D01180C-814A-B8B4-E040-BB89AD432507","latestVersionIndicator":"Yes","beginDate":"2010-08-04","endDate":null,"createdBy":"MAESKEB","dateCreated":"2010-08-04","modifiedBy":"KUMMEROA","dateModified":"2023-03-07","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/03/2015.","administrativeNotes":"2023.3.7 Alt VM added per ticket request CADSR0002119. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A9DDA641-6078-24A5-E053-4EBD850A86D6","beginDate":"2020-07-07","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-07-07","modifiedBy":"ONEDATA","dateModified":"2020-07-07","deletedIndicator":"No"},{"value":"None of the above","valueDescription":"None of the Above","ValueMeaning":{"publicId":"5913672","version":"1","preferredName":"None of the Above","longName":"5913672","preferredDefinition":"None of the choices above are suitable.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None of the Above","conceptCode":"C133298","definition":"None of the choices above are suitable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5499ACEF-10D1-1155-E053-F662850A3955","latestVersionIndicator":"Yes","beginDate":"2017-07-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-07-18","modifiedBy":"KUMMEROA","dateModified":"2022-07-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A9DDA641-6082-24A5-E053-4EBD850A86D6","beginDate":"2020-07-07","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-07-07","modifiedBy":"ONEDATA","dateModified":"2020-07-07","deletedIndicator":"No"},{"value":"ACNS1931","valueDescription":"ACNS1931","ValueMeaning":{"publicId":"7349542","version":"1","preferredName":"ACNS1931","longName":"7349542","preferredDefinition":"A Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A9DFD718-5315-3AEB-E053-4EBD850A3FF8","latestVersionIndicator":"Yes","beginDate":"2020-07-07","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-07-07","modifiedBy":"ONEDATA","dateModified":"2020-07-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A9DFD718-532E-3AEB-E053-4EBD850A3FF8","beginDate":"2020-07-07","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-07-07","modifiedBy":"ONEDATA","dateModified":"2020-07-07","deletedIndicator":"No"},{"value":"ACNS2021","valueDescription":null,"ValueMeaning":{"publicId":"14103918","version":"1","preferredName":"ACNS2021","longName":"14103918v1.00","preferredDefinition":"A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular and Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"00DFBF65-BD50-0A43-E063-731AD00A713F","latestVersionIndicator":"Yes","beginDate":"2023-07-19","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-19","modifiedBy":"GDEEN","dateModified":"2023-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"00DFBF65-BD51-0A43-E063-731AD00A713F","beginDate":"2023-07-19","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-19","modifiedBy":"GDEEN","dateModified":"2023-07-19","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008529","version":"1","preferredName":"Research Protocols","preferredDefinition":"the identification of cancer research protocols.","longName":"RSCH_PROT","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1ECC2BE-2F27-348A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3226369","version":"1","preferredName":"Children's Oncology Group Protocol Identifier","preferredDefinition":"The Children's Oncology Group (COG) is an NCI-supported clinical cooperative group (Arcadia, CA) formed by the merger of the four national pediatric cancer research organizations: the Children's Cancer Group, the Intergroup Rhabdomyosarcoma Study Group, the National Wilms Tumor Study Group, and the Pediatric Oncology Group. The primary objective of the organization is to conduct clinical trials of new therapies for childhood and adolescent cancer. COG develops and coordinates clinical trials conducted at the 238 member institutions that include cancer centers of all major universities and teaching hospitals throughout the U.S. and Canada, as well as sites in Europe and Australia. COG members include over 5000 cancer researchers.:A protocol is a rule which guides how an activity should be performed; a set of formal rules used to specify the format of an exchange of data.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.","longName":"C39353:C42651:C25364","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Children's Oncology Group","conceptCode":"C39353","definition":"An NCI-supported clinical cooperative group formed by the merger of the four national pediatric cancer research organizations: the Children's Cancer Group, the Intergroup Rhabdomyosarcoma Study Group, the National Wilms Tumor Study Group, and the Pediatric Oncology Group. The primary objective of the organization is to conduct clinical trials of new therapies for childhood and adolescent cancer. COG develops and coordinates clinical trials conducted at the 238 member institutions that include cancer centers of all major universities and teaching hospitals throughout the U.S. and Canada, as well as sites in Europe and Australia. COG members include over 5000 cancer researchers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Protocol","conceptCode":"C42651","definition":"A rule which guides how an activity should be performed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Identifier","conceptCode":"C25364","definition":"One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A06CBD41-6B33-B0E1-E040-BB89AD4364A3","latestVersionIndicator":"Yes","beginDate":"2011-04-08","endDate":null,"createdBy":"BLABOLIJ","dateCreated":"2011-04-08","modifiedBy":"ONEDATA","dateModified":"2011-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A9DDA641-5453-24A5-E053-4EBD850A86D6","latestVersionIndicator":"Yes","beginDate":"2020-07-07","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-07-07","modifiedBy":"GDEEN","dateModified":"2023-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Based on review of the rapid central pathology and molecular results, indicate which LGG study the patient is potentially eligible for:","url":null,"context":"COG"},{"name":"Which protocol is the patient","type":"Preferred Question Text","description":"Which protocol is the patient eligible for?","url":null,"context":"COG"},{"name":"COG CRF Text 3","type":"Alternate Question Text","description":"Based on central imaging and tumor marker review, which study is the patient potentially eligible for?","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA596AA3-EB50-5EE8-E053-4EBD850A16C1","latestVersionIndicator":"Yes","beginDate":"2020-07-13","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-07-13","modifiedBy":"GDEEN","dateModified":"2023-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}